News from the Nodes
Health Systems
 Kelly Young-Wolff, PhD, MPH, Health Systems Node faculty, conducted an analysis of more than 100,000 pregnancies in Kaiser Permanente Northern California and found a 25% increase in the rate of cannabis use early in pregnancy after the pandemic began in spring 2020.
Dr. Young-Wolff’s analysis was reported in a research letter in the September 27 issue of JAMA. The study found that in the year before the pandemic, 6.75% of pregnant women were using cannabis in early pregnancy, and during the pandemic that rate rose to 8.14% of pregnant women.
For a full description of the study, read more here.
Ohio Valley
 CTN-0125: Using Integrative Data Analysis to Examine the Impact of Psychosocial Treatments for Black Cocaine Users Enrolled in the NIDA Drug Abuse Treatment Clinical Trials Network (CTN)
This new study will evaluate the effectiveness of substance use disorder treatments for Black people who use cocaine and is a joint effort between the OVN, the WSN, and the NEC. Kathy Burlew (UC/OVN) and Lesia Ruglass (CCNY/WSN) are Co-LIs for this project.
CTN-0129: The Great Plains Initiative
This new project will work with American Indian populations in the Great Plains to determine community-defined needs for identifying and addressing SUD issues and assess the feasibility and acceptability of telemedicine for MOUD. Dr. Donald Warne (UND/OVN) is the LI for this project.
Western States
 The Western States Node is hosting its next speaker in their Addiction Sciences webinar series:
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Presenter: Dr. Christopher Stauffer
October 18, 2021 | 11:00am - 12:00pm PST
Connect via Zoom here.
|
Pacific Northwest
 Michael McDonell, PhD, of WSU and the CTN Pacific Northwest Node and Richard Rawson, PhD of UCLA are editing a special issue of the Journal of Substance Abuse Treatment focused on the changing epidemiology and treatment of stimulant use disorder.
The editors invite quality research manuscripts on topics related to stimulant use such as:
- Behavioral and pharmacotherapy innovations
- Implementation and dissemination science
- Treatment in medical and specialty care settings
- Assessment and treatment of co-occurring psychiatric symptoms (psychosis, depression, e.g.)
- Withdrawal management
- Overdose prevention and treatment
- Epidemiological and treatment studies involving underserved populations
To facilitate manuscript development, authors should submit an abstract (maximum of one page) of the proposed paper to Michael McDonell. The deadline for abstract submission is January 1, 2022.
Find out more here.
Protocol Update: CTN-0100
 100 participants have been randomized in CTN-0100! The team at the Mountain Manor site in Baltimore, led by site PI Marc Fishman, has randomized the 81st participant in the Retention Phase and the 100th participant overall.
The final Wave 1 site, Huntsman Mental Health Institute (Utah), has been endorsed and has started engaging study participants.
Wave 2 sites all have sIRB approval and continue to prepare for endorsement, with the first of those expected to start late October or early November. Wave 2 sites are: Aspire Health Partners (Florida), Dartmouth-Hitchcock ATP (New Hampshire), Operation PAR (Florida), University of Pittsburgh IM-REP and CPCDS clinics (Pennsylvania), Shoreline (South Carolina), Tarzana (California), CAST at UAMS (Arkansas) and ASAP at UNM (New Mexico).
For study information, please contact RDD at rdd@nyulangone.org.
|
NIDA is pleased to announce that they are renaming the AIDS Research Program (ARP) to the NIDA HIV Research Program (HRP) to better characterize our scientific investment at the intersection of HIV and substance use disorders. The name change aligns their HIV related science with less stigmatizing language, and reflects more contemporary HIV research and management approaches and priorities.
